Scorpio A, Blank T E, Day W A, Chabot D J
Bacteriology Division, United States Army Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, Maryland 21701, USA.
Cell Mol Life Sci. 2006 Oct;63(19-20):2237-48. doi: 10.1007/s00018-006-6312-3.
Anthrax has been a major cause of death in grazing animals and an occasional cause of death in humans for thousands of years. Since the late 1800s there has been an exceptional international history of anthrax vaccine development. Due to animal vaccinations, the rate of infection has dropped dramatically. Anthrax vaccines have progressed from uncharacterized whole-cell vaccines in 1881, to pXO2-negative spores in the 1930s, to culture filtrates absorbed to aluminum hydroxide in 1970, and likely to recombinant protective antigen in the near future. Each of these refinements has increased safety without significant loss of efficacy. The threat of genetically engineered, antibiotic and vaccine resistant strains of Bacillus anthracis is fueling hypothesis-driven research and global techniques--including genomics, proteomics and transposon site hybridization--to facilitate the discovery of novel vaccine targets. This review highlights historical achievements and new developments in anthrax vaccine research.
几千年来,炭疽一直是食草动物死亡的主要原因,偶尔也会导致人类死亡。自19世纪后期以来,炭疽疫苗的研发在国际上有着非凡的历史。由于动物接种疫苗,感染率已大幅下降。炭疽疫苗已从1881年未定性的全细胞疫苗,发展到20世纪30年代的pXO2阴性孢子疫苗,再到1970年吸附于氢氧化铝的培养滤液疫苗,并且在不久的将来可能会发展为重组保护性抗原疫苗。这些改进中的每一项都提高了安全性,而没有显著降低效力。炭疽杆菌的基因工程、抗生素和疫苗抗性菌株构成的威胁,正推动着基于假设的研究和全球技术——包括基因组学、蛋白质组学和转座子位点杂交——以促进新型疫苗靶点的发现。本综述重点介绍了炭疽疫苗研究的历史成就和新进展。